PT Kalbe Farma Tbk · IDX:KLBF
PT Kalbe Farma Tbk — H1 2023 Earnings Presentation
43 slides from PT Kalbe Farma Tbk's earnings presentation, August 2023
Slide 1: Company Update
Thrive through innovation and digitalization. Company Update 1H23 Unaudited Results PT Kalbe Farma Tbk August 2023
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 30 June 2023 unaudited results of the Company. The information contai
Slide 3: Table of Contents
Table of Contents Key Updates 4 Business Overview 10 Financial Overview 23 Appendix 29
Slide 4: Key Updates
Rina. Key Updates WWW.KALBE.CO.ID
Slide 5: Market Overview
Market Overview Relatively stable macroeconomy with changes in consumer spending post Covid Indonesia Macroeconomics • Stable and positive key macroeconomic indicators due to higher mobility • Managing risks of high inflation, decreasing purchasing power, customers spending allocation trend, amidst
Slide 6: Growth Areas
Growth Areas Positive top line growth driven by sustainable business initiatives 1H23 1H23 Net Sales EPS Growth Growth 9.4% -6.4% Innovation for Sustainable Growth Local Content Distribution Network & B2B Digital Initiatives Focus on innovation in all line of business: Innovation to manufacture loca
Slide 7: Focus on Customer Needs
Focus on Customer Needs Prioritizing quality and the best services to the customers …catering to all life stages, Expecting Mothers Lactating Mothers Kids Teens Adults Senior Clinical …locally and internationally, …with comprehensive healthcare solutions Complete range of pharma products Pioneering
Slide 8: Access to Healthcare for a better life
Access to Healthcare for a better life Gradual improvement of ESG according to international standard Environment Energy efficiency | 5,325 CO2 emission reduction Plastic waste & packaging | 634 kg plastic waste Gradually moving towards energy efficiency and #gregetplastik campaign & gradual adoptio
Slide 9: Business Overview
Business Overview WWW.KALBE.CO.ID
Slide 10: Corporate Overview
Segment breakdown Corporate Overview More than half a century of providing wide-range healthcare solutions market capitalization The largest publicly-listed pharmaceuticals company in Southeast Asia IDR 96.1 tn ($6.4 bn) * Onwards 1966 1991 free float Established, headquartered The most integrated 4
Slide 11: Prescription Pharmaceuticals
Segment breakdown Prescription Pharmaceuticals Double-digit net sales growth post Covid Net Sales IDR bn (unaudited) + 31.9% Kalbe 3,879 Unbranded Net Sales Growth Licensed 11% (yoy) 25% Generics 2,941 a 24% 9% Market Share b Contribution 6% others 11% c 58% 6% d e 4% Branded f 3% Jun 2222 Jun 2323
Slide 12: Prescription Pharmaceuticals
Segment breakdown Prescription Pharmaceuticals Accelerating strategic collaborations, supporting the government program, and compliance to product quality standard Oncology Expanding collaboration through M&A and strategic partnership - Sanofi Indonesia • Strengthening portfolio in focused therapeut
Slide 13: Prescription Pharmaceuticals: Biologics Journey
Segment breakdown Prescription Pharmaceuticals Biologics Journey: Commitment in R&D efforts to achieve biological drugs development milestones Strategy Portfolio • Strengthening presence in specialty products through engagement with Strategic Novel Products Partners Focus on immuno-oncology products
Slide 14: Consumer Health
Segment breakdown Consumer Health Softening market amidst normalization of covid cases and change in consumer spending Net Sales IDR bn (unaudited) - 4.2% Kalbe 2,146 2,055 8% Net Sales Growth Health a 5% (yoy) Supplement b 4% 24% c 3% d 3% Contribution Market Share e 3% 8% f 3% g 3% others OTC 68%
Slide 15: Consumer Health
Segment breakdown Consumer Health Market Share: Leveraging our strong brands and maintaining customer loyalty Antacids Anti Diarrhea Cough Remedies Children Multivitamin Health Supplement Cold Remedies 72% 56% 50% 52% 52% 39% Promag Entrostop Komix, Woods Sakatonik ABC Extra Joss Mixagrip, Procold P
Slide 16: Nutritionals
Segment breakdown Nutritionals Maintaining higher-than-market top-line growth in the challenging market Net Sales IDR bn (unaudited) 3,934 3,720 + 5.7% others 9.0% Kalbe Specialty f Net Sales Growth 16% 4% 14% (yoy) e d 4% 5% Adults Contribution Market Share c a 24% Kids 15% 14% 29% 60% Jun Jun2222
Slide 17: Nutritionals
Segment breakdown Nutritionals Extensive products coverage to serve all ages and segments new 17 *New SKUs
Slide 18: Distribution and Logistics
Segment breakdown Distribution and Logistics The largest distribution network in healthcare, with focus on digital expansion and capturing the medical devices market potentials Net Sales Medical Raw Devices Materials Highlights IDR bn (unaudited) Trading 5% + 4.8% 9% • Positive top-line growth in 1
Slide 19: Distribution and Logistics
Segment breakdown Distribution and Logistics The largest distribution network in healthcare with focus on digital expansion Major Third-Party Principals by Category The Most Extensive Distribution Network Prescription Pharmaceuticals Consumer +200K Outlets 72 Branches 3 Regional Distribution Centre
Slide 20: Distribution and Logistics
Segment breakdown Distribution and Logistics Capturing medical devices market potentials Local Content Regulation on Medical Devices • Completion of surgical suture production facility to comply with TKDN • Building own brand “E-Care” for consumables products and “Elvasense” for personal healthcare
Slide 21: Financial Overview
Pal ( KALBE Financial Overview WWWw.KALBE.CO.ID
Slide 22: Consolidated Operational Performance
Consolidated Operational Performance Maintained positive growth in challenging market Net Sales 9.4% In IDR bn (unaudited) 15,179 13,875 31.9% -4.2% 5.7% 4.8% 5,068 5,312 3,879 3,720 3,934 2,941 2,146 2,055 Prescription Consumer Health Nutritionals Distribution & Logistics Total Consolidated Pharmac
Slide 23: Consolidated Operational Performance
Consolidated Operational Performance Temporary pressure on margin Gross Profit Operating Expenses to Net Sales Net Income 6.5% -6.6% 27.2% 27.3% 11.8% 10.1% 41.8% 40.7% 1.1% 1.4% 5.0% 5.1% Selling Expenses G&A Expenses 5,798 6,176 1,637 21.1% 20.9% 1,529 R&D Expenses Jun 22 Jun 23 Jun 22 Jun 23 Jun
Slide 24: Working Capital Management
Working Capital Management Securing product quality and availability by managing inventory 180 169 162 Managing Net Operating Cycle 160 • Net Operating Cycle remained at 169 days in 2Q23 mostly 140 131 129 148 reflecting sustained inventory level 126 147 120 • Strategy to manage supply chain challen
Slide 25: Capital Allocation
Capital Allocation Healthy cash balance to support operation and business expansion Total Debt & Gearing Ratio Cash & Net Cash Total Debt Gearing Ratio Cash & cash equivalent Net Cash 2,000 8.3% 9.0% 6,216 1,800 8.0% 5,590 1,600 5,208 5.8% 7.0% 1,400 4.9% 5.1% 6.0% 4,050 3,950 1,200 5.0% 1,000 3,040
Slide 26: Revised Outlook 2023
Revised Outlook 2023 Focus on innovation and digitalization to drive core products growth YoY Sales Growth EPS Growth Dividend Payout 8-10% 0-1% Ratio 45-55% 1H23: 9.4% 1H23: - 6.4% Growing above the market rate Managing working capital and non- Consistently maximizing shareholders' operating items
Slide 27: Appendix 1
Rina. Appendix 1 WWW.KALBE.CO.ID
Slide 28: Healthcare Industry Overview
Healthcare Industry Overview Growing national health insurance coverage and increasing health budget In IDR tn Regular Health Budget National Health Insurance (JKN) 2023 169.8 Coverage IDR 169.8 tn grows 30.2% compared to 300 100% 2022 130.4 82.4 regular health budget 2022 90.7% 83.9% 86.1% 90% 82.3
Slide 29: Recent Pharma Regulations
Recent Pharma Regulations Ensuring compliance and support to government strategic programs Healthcare Omnibus Law • Improving doctors availability, local content requirement, distribution of free-sales drugs Decree of MoH No. HK 01.07/Menkes/1333/2023 • Increasing the uses of pharma products with lo
Slide 30: Sustainability Activities
Sustainability Activities Improving access to healthcare and implementing responsible business practices Kalbe Junior Scientist Award Provide opportunities to the elementary school students to the science experiments at home Red Ginger Farmers Solar Panel Empower the farmers and initiate Support ene
Slide 31: Strengthening our Human Capital
Strengthening our Human Capital Committed to enhance skill and capacity of employees for innovation and digitalization Management Program Vocational Program Kalbe Learning Center (KLC) as certified • Kalbe Middle Management Program (KMMP) vocational school partner: • Kalbe First Line Management Prog
Slide 32: Appendix 2
Appendix 2
Slide 33: Financial Statement
Financial Statement CONSOLIDATED STATEMENT Dec 22 Jun 23 Change ytd OF FINANCIAL POSITION (Audited) (Unaudited) ASSETS CURRENT ASSETS Cash and Cash Equivalents 3,949,768,854,987 2,742,601,288,772 -30.6% Trade Receivables 4,613,623,001,325 5,252,549,615,665 13.8% Other Receivables 174,144,805,758 185
Slide 34: Financial Statement
Financial Statement CONSOLIDATED STATEMENT Dec 22 Jun 23 Change ytd OF FINANCIAL POSITION (Audited) (Unaudited) ASSETS LIABILITIESASSETS CURRENT CURRENT Cash LIABILITIES and Cash Equivalents 3,949,768,854,987 2,742,601,288,772 -30.6% Short-term Bank Loans 705,600,000,000 1,458,200,000,000 106.7% Tra
Slide 35: Financial Statement
Financial Statement CONSOLIDATED STATEMENT Dec 22 Jun 23 Change ytd OF FINANCIAL POSITION (Audited) (Unaudited) ASSETS EQUITY CURRENT Capital ASSETS Stock -Issued and Fully Paid 468,751,221,100 468,751,221,100 0.0% Cash and Cash Additional Equivalents Paid-in Capital, Net 3,949,768,854,987 (34,118,6
Slide 36: Financial Statement
Financial Statement CONSOLIDATED STATEMENT OF PROFIT OR LOSS Jun 22 Jun 23 Change yoy AND OTHER COMPREHENSIVE INCOME (Unaudited) (Unaudited) NET SALES 13,874,586,036,387 15,178,929,358,642 9.4% COST OF GOODS SOLD (8,076,394,585,804) (9,003,330,594,172) 11.5% % to NS 58.2% 59.3% 1.1% GROSS PROFIT 5,7
Slide 37: Financial Statement
Financial Statement CONSOLIDATED STATEMENT OF PROFIT OR LOSS Jun 22 Jun 23 Change yoy AND OTHER COMPREHENSIVE INCOME (Unaudited) (Unaudited) NET SALES INCOME BEFORE INCOME TAX EXPENSE 13,874,586,036,387 2,135,681,299,704 15,178,929,358,642 1,939,411,543,220 9.4% -9.2% COST OF % to NS GOODS SOLD (8,0
Slide 38: Financial Statement
Financial Statement CONSOLIDATED STATEMENT OF PROFIT OR LOSS Jun 22 Jun 23 Change yoy AND OTHER COMPREHENSIVE INCOME (Unaudited) (Unaudited) Income NET for the Year Attributable to: SALES 13,874,586,036,387 15,178,929,358,642 9.4% Owners COST of the Parent OF GOODS SOLD Company 1,636,948,664,226 (8,
Slide 39: Financial Statement
Financial Statement Jun 22 Jun 23 CONSOLIDATED STATEMENT OF CASH FLOWS Change yoy (Unaudited) (Unaudited) CASH FLOWS FROM OPERATING ACTIVITIES Cash received from customers 14,717,921,542,120 15,948,950,168,083 8.4% Cash payments to suppliers and employees (10,532,374,106,336) (11,240,882,300,248) 6.
Slide 40: Financial Statement
Financial Statement Jun 22 Jun 23 CONSOLIDATED STATEMENT OF CASH FLOWS Change yoy (Unaudited) (Unaudited) CASH FLOWS CASH FLOWSFROM FROM OPERATING INVESTING ACTIVITIES ACTIVITIES Cash receivedfrom Proceeds fromsale customers of investment in associate 14,717,921,542,120 - 15,948,950,168,083 71,085,1
Slide 41: Financial Statement
Financial Statement Jun 22 Jun 23 CONSOLIDATED STATEMENT OF CASH FLOWS Change yoy (Unaudited) (Unaudited) CASH CASH FLOWS FLOWS FROM FROM OPERATING ACTIVITIES FINANCING ACTIVITIES Cash received Proceeds fromfrom customers short-term bank loans 14,717,921,542,120 242,000,000,000 15,948,950,168,083 1,
Slide 42: Financial Statement
Financial Statement Jun 22 Jun 23 CONSOLIDATED STATEMENT OF CASH FLOWS Change yoy (Unaudited) (Unaudited) CASHINCREASE NET FLOWS FROM OPERATING (DECREASE) ACTIVITIES IN CASH Cash received from customers (2,143,442,139,523) 14,717,921,542,120 (1,122,626,979,949) 15,948,950,168,083 -47.6% 8.4% AND CAS
Slide 43: Thank you
Thank you For further information: PT Kalbe Farma Tbk. Jalan Let. Jend. Suprapto Kav. 4 Jakarta 10510, Indonesia Tel. : 62-21-42873888 Fax. : 62-21-42873678 Email: [email protected] [email protected] 43